BACKGROUND: The alpha-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists. METHODS: The present study was conducted to prospectively investigate the relationship among the ADD1 Gly460Trp polymorphism, diuretic use, and adverse cardiovascular outcomes among 5,979 patients with hypertensive coronary artery disease, who participated in the INVEST and provided genomic DNA. The primary outcome was defined as the first occurrence of nonfatal stroke, nonfatal myocardial infarction, or all-cause death. Secondary outcomes were the components of the primary outcome. Ancestry informative markers were used to control for population stratification. RESULTS: In blacks, ADD1 variant carriers were at higher risk for a primary outcome event than wild-type homozygotes (adjusted hazard ratio 2.62, 95% CI 1.23-5.58, P = .012), with a similar trend in whites and Hispanics, albeit a smaller magnitude of effect (adjusted hazard ratio 1.43, 0.86-2.39 in Hispanics; 1.24, 0.90-1.71 in whites). Secondary outcome analysis showed that the all-cause death was driving the differences in primary outcomes by genotype. There was no interaction between the ADD1 polymorphism and diuretic use for either primary outcome or secondary outcomes. CONCLUSIONS: In hypertensive patients with coronary artery disease, black ADD1 variant carriers showed a 2.6-fold excess risk for a primary outcome event and an 8-fold increase risk of death. White and Hispanic ADD1 variant carriers showed an increased but nonsignificant excess risk. However, the effect of diuretic use on risk of cardiovascular outcomes did not vary by ADD1 carrier status.
RCT Entities:
BACKGROUND: The alpha-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists. METHODS: The present study was conducted to prospectively investigate the relationship among the ADD1 Gly460Trp polymorphism, diuretic use, and adverse cardiovascular outcomes among 5,979 patients with hypertensivecoronary artery disease, who participated in the INVEST and provided genomic DNA. The primary outcome was defined as the first occurrence of nonfatal stroke, nonfatal myocardial infarction, or all-cause death. Secondary outcomes were the components of the primary outcome. Ancestry informative markers were used to control for population stratification. RESULTS: In blacks, ADD1 variant carriers were at higher risk for a primary outcome event than wild-type homozygotes (adjusted hazard ratio 2.62, 95% CI 1.23-5.58, P = .012), with a similar trend in whites and Hispanics, albeit a smaller magnitude of effect (adjusted hazard ratio 1.43, 0.86-2.39 in Hispanics; 1.24, 0.90-1.71 in whites). Secondary outcome analysis showed that the all-cause death was driving the differences in primary outcomes by genotype. There was no interaction between the ADD1 polymorphism and diuretic use for either primary outcome or secondary outcomes. CONCLUSIONS: In hypertensivepatients with coronary artery disease, black ADD1 variant carriers showed a 2.6-fold excess risk for a primary outcome event and an 8-fold increase risk of death. White and Hispanic ADD1 variant carriers showed an increased but nonsignificant excess risk. However, the effect of diuretic use on risk of cardiovascular outcomes did not vary by ADD1 carrier status.
Authors: Bruce M Psaty; Nicholas L Smith; Susan R Heckbert; Hans L Vos; Rozenn N Lemaitre; Alexander P Reiner; David S Siscovick; Joshua Bis; Thomas Lumley; W T Longstreth; Frits R Rosendaal Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: C Barlassina; N J Schork; P Manunta; L Citterio; M Sciarrone; G Lanella; G Bianchi; D Cusi Journal: Kidney Int Date: 2000-03 Impact factor: 10.612
Authors: Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das Journal: Pharmacogenomics Date: 2012-03 Impact factor: 2.533
Authors: Elvin Tyrone Price; Michael A Pacanowski; Michael A Martin; Rhonda M Cooper-DeHoff; Carl J Pepine; Issam Zineh; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: Fan Fan; Aron M Geurts; Mallikarjuna R Pabbidi; Ying Ge; Chao Zhang; Shaoxun Wang; Yedan Liu; Wenjun Gao; Ya Guo; Longyang Li; Xiaochen He; Wenshan Lv; Yoshikazu Muroya; Takashi Hirata; Jeremy Prokop; George W Booz; Howard J Jacob; Richard J Roman Journal: J Am Soc Nephrol Date: 2020-02-06 Impact factor: 10.121
Authors: Denise G Simons-Morton; Jeffrey C Chan; Angela R Kimel; Peter E Linz; Cynthia L Stowe; John Summerson; Walter T Ambrosius Journal: Contemp Clin Trials Date: 2013-12-17 Impact factor: 2.226